This clinical review examined the role of therapeutic bronchoscopy for malignant central airway obstruction, focusing on patient-centered outcomes as well as procedural risk. Central airway obstruction can cause severe dyspnoea, cough, recurrent infection, and impaired quality of life, sometimes creating an urgent need for symptom relief even when definitive cancer therapy is still being planned. The review emphasizes that bronchoscopic intervention can produce meaningful palliation and can be integrated with other oncologic treatments when appropriately selected. At the same time, these procedures carry risks, and the benefit–risk balance depends on anatomy, tumor burden, performance status, and local expertise. The paper is valuable for HCPs because it frames intervention as part of a multidisciplinary decision rather than simply a technical procedure. The conference’s emphasis on early referral for airway intervention and on building an MDT habit is well aligned with this approach. In practical terms, the right question is often not “Can this lesion be treated bronchoscopically?” but “Will timely airway intervention improve symptoms, safety, or the patient’s ability to receive the next stage of treatment?”